JPRN-UMIN000029310招募中未知
Impact of anti-PCSK9 antibody Alirocumab on lipid-lowering on patient motivation to treatment for hypercholesterolemia. - Impact of Alirocumab on patient motivation to treatment.
Minamiosaka Hospital Department of Internal Medicine0 个研究点目标入组 10 人开始时间: 2017年10月1日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Pregnant 2)Drug allergy to Alirocumab 3)Unsuitable patients for this study by physicians decision
研究者
相似试验
终止
2 期
Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic SyndromeNephrotic SyndromeNCT03004001Gloria Vega3
已完成
1 期
Alirocumab in Patients with SepsisSepsisNCT05469347Jonathan Sevransky50
已完成
不适用
egacy Effects of PCSK9 Inhibitors on Lipid-Rich Vulnerable Coronary Plaqueacute coronary syndromeJPRN-UMIN000041925Gifu Heart Center7
已完成
2 期
Effect of Alirocumab on Lipoprotein(a) (Lp(a)) Metabolism in Subjects with Moderate to High Risk of Heart DiseaseCardiovascular Disease (CVD)Cardiovascular - Coronary heart diseaseACTRN12617000401358inear Clinical Research Ltd.21
进行中（未招募）
2 期
Trial of PCSK9 Inhibition in Patients with Acute Stroke and Symptomatic Intracranial AtherosclerosisIntracranial AtherosclerosisAcute Ischemic StrokeICAS - Intracranial AtherosclerosisNCT05001984Chang Gung Memorial Hospital60